Vertex Pharma (VRTX) Offering Possible 33.33% Return Over the Next 21 Calendar Days

Vertex Pharma's most recent trend suggests a bearish bias. One trading opportunity on Vertex Pharma is a Bear Call Spread using a strike $215.00 short call and a strike $225.00 long call offers a potential 33.33% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $215.00 by expiration. The full premium credit of $2.50 would be kept by the premium seller. The risk of $7.50 would be incurred if the stock rose above the $225.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Vertex Pharma is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Vertex Pharma is bearish.

The RSI indicator is below 20 which suggests that the stock is in oversold territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Vertex Pharma

What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
Wed, 28 Oct 2020 16:55:04 +0000
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

Benzinga's Top Upgrades, Downgrades For October 28, 2020
Wed, 28 Oct 2020 16:38:34 +0000
Upgrades * For Omnicom Group Inc (NYSE: OMC), MoffettNathanson upgraded the previous rating of Sell to the current rating Neutral. Omnicom Group earned $1.21 in the third quarter, compared to $1.32 in the year-ago quarter. At the moment, the stock has a 52-week-high of 82.73 and a 52-week-low of 46.37. Omnicom Group closed at $48.81 at the end of the last trading period. * For Advanced Micro Devices Inc (NASDAQ: AMD), Craig-Hallum upgraded the previous rating of Hold to the current rating Buy. For the third quarter, Advanced Micro Devices had an EPS of $0.41, compared to year-ago quarter EPS of $0.18. At the moment, the stock has a 52-week-high of 94.28 and a 52-week-low of 31.83. Advanced Micro Devices closed at $78.88 at the end of the last trading period. * B. Riley FBR upgraded the previous rating for ViewRay Inc (NASDAQ: VRAY) from Neutral to Buy. For the second quarter, ViewRay had an EPS of $0.18, compared to year-ago quarter EPS of $0.32. The current stock performance of ViewRay shows a 52-week-high of 4.88 and a 52-week-low of 1.1055. Moreover, at the end of the last trading period, the closing price was at $3.00. * Deutsche Bank upgraded the previous rating for Lululemon Athletica Inc (NASDAQ: LULU) from Hold to Buy. For the second quarter, Lululemon Athletica had an EPS of $0.74, compared to year-ago quarter EPS of $0.96. The stock has a 52-week-high of 399.8965 and a 52-week-low of 128.845. At the end of the last trading period, Lululemon Athletica closed at $333.81. * According to JP Morgan, the prior rating for Xilinx Inc (NASDAQ: XLNX) was changed from Underweight to Neutral. Xilinx earned $0.79 in the second quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of 130.4 and a 52-week-low of 67.68. At the end of the last trading period, Xilinx closed at $124.35. * JP Morgan upgraded the previous rating for Sherwin-Williams Co (NYSE: SHW) from Neutral to Overweight. In the third quarter, Sherwin-Williams showed an EPS of $8.29, compared to $6.65 from the year-ago quarter. The current stock performance of Sherwin-Williams shows a 52-week-high of 725.91 and a 52-week-low of 325.43. Moreover, at the end of the last trading period, the closing price was at $673.04. * For MSC Industrial Direct Co Inc (NYSE: MSM), Raymond James upgraded the previous rating of Underperform to the current rating Market Perform. In the fourth quarter, MSC Industrial Direct Co showed an EPS of $1.09, compared to $1.30 from the year-ago quarter. At the moment, the stock has a 52-week-high of 79.87 and a 52-week-low of 44.93. MSC Industrial Direct Co closed at $67.72 at the end of the last trading period. * Barclays upgraded the previous rating for First Solar Inc (NASDAQ: FSLR) from Underweight to Equal-Weight. First Solar earned $1.45 in the third quarter, compared to $0.29 in the year-ago quarter. The stock has a 52-week-high of 87.44 and a 52-week-low of 28.47. At the end of the last trading period, First Solar closed at $82.39. * For Advanced Micro Devices Inc (NASDAQ: AMD), Barclays upgraded the previous rating of Equal-Weight to the current rating Overweight. For the third quarter, Advanced Micro Devices had an EPS of $0.41, compared to year-ago quarter EPS of $0.18. The current stock performance of Advanced Micro Devices shows a 52-week-high of 94.28 and a 52-week-low of 31.83. Moreover, at the end of the last trading period, the closing price was at $78.88. * According to Keefe, Bruyette & Woods, the prior rating for Invesco Ltd (NYSE: IVZ) was changed from Market Perform to Outperform. For the third quarter, Invesco had an EPS of $0.53, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of 19.01 and a 52-week-low of 6.375. At the end of the last trading period, Invesco closed at $13.96. Downgrades * According to Craig-Hallum, the prior rating for Enphase Energy Inc (NASDAQ: ENPH) was changed from Buy to Hold. For the third quarter, Enphase Energy had an EPS of $0.30, compared to year-ago quarter EPS of $0.30. The stock has a 52-week-high of 118.939 and a 52-week-low of 17.18. At the end of the last trading period, Enphase Energy closed at $98.63. * For Enphase Energy Inc (NASDAQ: ENPH), HC Wainwright & Co. downgraded the previous rating of Buy to the current rating Neutral. For the third quarter, Enphase Energy had an EPS of $0.30, compared to year-ago quarter EPS of $0.30. The current stock performance of Enphase Energy shows a 52-week-high of 118.939 and a 52-week-low of 17.18. Moreover, at the end of the last trading period, the closing price was at $98.63. * According to Goldman Sachs, the prior rating for Relmada Therapeutics Inc (NASDAQ: RLMD) was changed from Buy to Neutral. At the moment, the stock has a 52-week-high of 54.0 and a 52-week-low of 21.85. Relmada Therapeutics closed at $33.06 at the end of the last trading period. * For Exact Sciences Corp (NASDAQ: EXAS), Citigroup downgraded the previous rating of Buy to the current rating Neutral. In the third quarter, Exact Sciences showed an EPS of $0.07, compared to $0.31 from the year-ago quarter. The current stock performance of Exact Sciences shows a 52-week-high of 141.9 and a 52-week-low of 35.2512. Moreover, at the end of the last trading period, the closing price was at $131.12. * For Everbridge Inc (NASDAQ: EVBG), B of A Securities downgraded the previous rating of Buy to the current rating Neutral. In the second quarter, Everbridge showed an EPS of $0.06, compared to $0.07 from the year-ago quarter. The current stock performance of Everbridge shows a 52-week-high of 165.79 and a 52-week-low of 66.19. Moreover, at the end of the last trading period, the closing price was at $128.68. * For Armstrong World Industries Inc (NYSE: AWI), B of A Securities downgraded the previous rating of Buy to the current rating Neutral. The stock has a 52-week-high of 111.46 and a 52-week-low of 61.56. At the end of the last trading period, Armstrong World Indus closed at $62.91. * According to Stifel, the prior rating for New Fortress Energy Inc (NASDAQ: NFE) was changed from Buy to Hold. New Fortress Energy earned $0.24 in the second quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of 54.92 and a 52-week-low of 7.01. New Fortress Energy closed at $49.16 at the end of the last trading period. * According to Morgan Stanley, the prior rating for Harley-Davidson Inc (NYSE: HOG) was changed from Overweight to Equal-Weight. The stock has a 52-week-high of 40.86 and a 52-week-low of 14.31. At the end of the last trading period, Harley-Davidson closed at $35.37. * Evercore ISI Group downgraded the previous rating for Frontline Ltd (NYSE: FRO) from In-Line to Underperform. Frontline earned $1.04 in the second quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of 13.33 and a 52-week-low of 5.98. Frontline closed at $6.04 at the end of the last trading period. * According to JP Morgan, the prior rating for FB Financial Corp (NYSE: FBK) was changed from Neutral to Underweight. In the third quarter, FB Financial earned $1.46. At the moment, the stock has a 52-week-high of 40.33 and a 52-week-low of 14.38. FB Financial closed at $28.65 at the end of the last trading period. * Barclays downgraded the previous rating for Diamondback Energy Inc (NASDAQ: FANG) from Overweight to Equal-Weight. Diamondback Energy earned $0.15 in the second quarter, compared to $2.11 in the year-ago quarter. The stock has a 52-week-high of 96.92 and a 52-week-low of 14.55. At the end of the last trading period, Diamondback Energy closed at $26.57. * For DTE Energy Co (NYSE: DTE), BMO Capital downgraded the previous rating of Outperform to the current rating Market Perform. In the third quarter, DTE Energy showed an EPS of $2.61, compared to $1.91 from the year-ago quarter. At the moment, the stock has a 52-week-high of 135.67 and a 52-week-low of 71.21. DTE Energy closed at $127.25 at the end of the last trading period. * According to Credit Suisse, the prior rating for Veoneer Inc (NYSE: VNE) was changed from Neutral to Underperform. In the third quarter, Veoneer showed an EPS of $0.96, compared to $1.20 from the year-ago quarter. The stock has a 52-week-high of 18.9 and a 52-week-low of 5.25. At the end of the last trading period, Veoneer closed at $15.83. * For Varian Medical Systems Inc (NYSE: VAR), Baird downgraded the previous rating of Outperform to the current rating Neutral. For the fourth quarter, Varian Medical Systems had an EPS of $1.12, compared to year-ago quarter EPS of $1.21. The stock has a 52-week-high of 176.19 and a 52-week-low of 89.62. At the end of the last trading period, Varian Medical Systems closed at $173.02. * According to Piper Sandler, the prior rating for Livongo Health Inc (NASDAQ: LVGO) was changed from Overweight to Neutral. For the third quarter, Livongo Health had an EPS of No EPS Value , compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of 151.049 and a 52-week-low of 18.76. Livongo Health closed at $142.89 at the end of the last trading period. Initiations * UBS initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ: VRTX) with a Buy rating. The price target for Vertex Pharmaceuticals is set to $287.00. Vertex Pharmaceuticals earned $2.61 in the second quarter, compared to $1.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of 306.08 and a 52-week-low of 192.32. Vertex Pharmaceuticals closed at $212.19 at the end of the last trading period. * With a current rating of Buy, Berenberg initiated coverage on Terreno Realty Corp (NYSE: TRNO). The price target seems to have been set at $70.00 for Terreno Realty. Terreno Realty earned $0.19 in the second quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of 64.24 and a 52-week-low of 42.115. Terreno Realty closed at $58.25 at the end of the last trading period. * UBS initiated coverage on Sarepta Therapeutics Inc (NASDAQ: SRPT) with a Buy rating. The price target for Sarepta Therapeutics is set to $212.00. For the second quarter, Sarepta Therapeutics had an EPS of $1.51, compared to year-ago quarter EPS of $0.83. At the moment, the stock has a 52-week-high of 175.0 and a 52-week-low of 78.06. Sarepta Therapeutics closed at $139.62 at the end of the last trading period. * Berenberg initiated coverage on Rexford Industrial Realty Inc (NYSE: REXR) with a Buy rating. The price target for Rexford Industrial Realty is set to $56.00. For the third quarter, Rexford Industrial Realty had an EPS of $0.33, compared to year-ago quarter EPS of $0.31. At the moment, the stock has a 52-week-high of 53.48 and a 52-week-low of 31.7871. Rexford Industrial Realty closed at $47.69 at the end of the last trading period. * With a current rating of Buy, Berenberg initiated coverage on Plymouth Industrial REIT Inc (NYSE: PLYM). The price target seems to have been set at $15.00 for Plymouth Industrial REIT. Plymouth Industrial REIT earned $0.45 in the second quarter, compared to $0.43 in the year-ago quarter. At the moment, the stock has a 52-week-high of 21.4964 and a 52-week-low of 7.79. Plymouth Industrial REIT closed at $12.75 at the end of the last trading period. * UBS initiated coverage on PTC Therapeutics Inc (NASDAQ: PTCT) with a Neutral rating. The price target for PTC Therapeutics is set to $55.00. PTC Therapeutics earned $2.62 in the second quarter, compared to $0.75 in the year-ago quarter. The current stock performance of PTC Therapeutics shows a 52-week-high of 59.89 and a 52-week-low of 30.7923. Moreover, at the end of the last trading period, the closing price was at $53.26. * Berenberg initiated coverage on Monmouth Real Estate Investment Corp (NYSE: MNR) with a Buy rating. The price target for Monmouth Real Estate Inv is set to $17.00. For the third quarter, Monmouth Real Estate Inv had an EPS of $0.20, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of 15.53 and a 52-week-low of 8.42. At the end of the last trading period, Monmouth Real Estate Inv closed at $14.22. * With a current rating of Buy, UBS initiated coverage on Immunovant Inc (NASDAQ: IMVT). The price target seems to have been set at $61.00 for Immunovant. Immunovant earned $0.38 in the first quarter. The current stock performance of Immunovant shows a 52-week-high of 43.9399 and a 52-week-low of 8.34. Moreover, at the end of the last trading period, the closing price was at $42.93. * With a current rating of Neutral, UBS initiated coverage on Gilead Sciences Inc (NASDAQ: GILD). The price target seems to have been set at $61.00 for Gilead Sciences. Gilead Sciences earned No EPS Value in the third quarter, compared to $1.75 in the year-ago quarter. The current stock performance of Gilead Sciences shows a 52-week-high of 85.97 and a 52-week-low of 59.395. Moreover, at the end of the last trading period, the closing price was at $60.01. * With a current rating of Buy, B of A Securities initiated coverage on Cal-Maine Foods Inc (NASDAQ: CALM). The price target seems to have been set at $47.00 for Cal-Maine Foods. In the first quarter, Cal-Maine Foods showed an EPS of $0.40, compared to $0.94 from the year-ago quarter. At the moment, the stock has a 52-week-high of 46.6576 and a 52-week-low of 30.74. Cal-Maine Foods closed at $38.87 at the end of the last trading period. * With a current rating of Neutral, UBS initiated coverage on Biogen Inc (NASDAQ: BIIB). The price target seems to have been set at $268.00 for Biogen. Biogen earned $8.84 in the third quarter, compared to $9.17 in the year-ago quarter. The current stock performance of Biogen shows a 52-week-high of 374.99 and a 52-week-low of 254.925. Moreover, at the end of the last trading period, the closing price was at $255.30. * With a current rating of Neutral, UBS initiated coverage on Amgen Inc (NASDAQ: AMGN). The price target seems to have been set at $232.00 for Amgen. Amgen earned No EPS Value in the third quarter, compared to $3.66 in the year-ago quarter. The stock has a 52-week-high of 264.97 and a 52-week-low of 177.05. At the end of the last trading period, Amgen closed at $223.46. * With a current rating of Neutral, UBS initiated coverage on Alexion Pharmaceuticals Inc (NASDAQ: ALXN). The price target seems to have been set at $133.00 for Alexion Pharmaceuticals. In the second quarter, Alexion Pharmaceuticals showed an EPS of $3.11, compared to $2.64 from the year-ago quarter. The current stock performance of Alexion Pharmaceuticals shows a 52-week-high of 128.57 and a 52-week-low of 72.67. Moreover, at the end of the last trading period, the closing price was at $120.00. * With a current rating of Neutral, JP Morgan initiated coverage on Hyliion Holdings Corp (NYSE: HYLN). The price target seems to have been set at $27.00 for Hyliion Holdings. The stock has a 52-week-high of 44.9 and a 52-week-low of 20.4. At the end of the last trading period, Hyliion Holdings closed at $21.31. * Jefferies initiated coverage on Burlington Stores Inc (NYSE: BURL) with a Buy rating. The price target for Burlington Stores is set to $255.00. In the second quarter, Burlington Stores showed an EPS of $0.56, compared to $1.36 from the year-ago quarter. The stock has a 52-week-high of 250.89 and a 52-week-low of 105.67. At the end of the last trading period, Burlington Stores closed at $200.18.See more from Benzinga * Click here for options trades from Benzinga * Analyzing SolarEdge Technologies's Unusual Options Activity * Analyzing Designer Brands's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
Wed, 28 Oct 2020 11:00:00 +0000
Vertex Pharmaceuticals (NASDAQ: VRTX) and Alexion Pharmaceuticals (NASDAQ: ALXN) are two major competitors in the healthcare sector, both of whom focus on developing drugs for rare diseases like cystic fibrosis and myasthenia gravis. Each company is profitable, makes around $5.45 billion in trailing revenue, and is rapidly growing its quarterly revenue.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
Tue, 27 Oct 2020 15:29:03 +0000
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

3 Biotech Stocks I'd Buy Right Now
Tue, 27 Oct 2020 14:08:00 +0000
Marketed products — and work in the pipeline — should translate into future growth for these shares.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.